OncoMatch/Clinical Trials/NCT06327269
Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma
Is NCT06327269 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Lenvatinib 10 mg for high risk of recurrence.
Treatment: Lenvatinib 10 mg — The challenge of LDLT to HCC is that tumors with a high risk of recurrence have a high rate of recurrence after liver transplantation, and there is no appropriate treatment to prevent HCC recurrence after transplantation in these patients. Using the advance proton therapy or yttrium 90 as a more aggressive down-staging therapy may contribute to change tumor behavior. It can be used to get a better treatment response and tumor necrosis before LDLT. As a result, it will improve recurrence-free survival and overall survival rate, especially in high-risk groups. In addition, lenvatinib is approved for using in patients with advanced liver cancer because its overall survival rate is not less than sorafenib in clinical trials. A new generation of targeted therapies will be applied to adjuvant therapy after LDLT.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: AFP poor AFP response (<15%) or AFP>400 ng/ml after LRT
patients who has poor AFP response (<15%) or AFP>400 ng/ml after LRT after conventional LRT (RFA、PEI or TACE)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify